Astrocytoma Clinical Trials in Philadelphia, Pennsylvania
9 recruitingPhiladelphia, Pennsylvania
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low-grade GliomaLow Grade AstrocytomaWHO Grade 2 Glioma+3 more
National Cancer Institute (NCI)170 enrolled132 locationsNCT04166409
Recruiting
Phase 3
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Astrocytoma, IDH-Mutant, Grade 3
Alliance for Clinical Trials in Oncology408 enrolled75 locationsNCT07215910
Recruiting
Phase 2
Study of Olutasidenib and Temozolomide in HGG
Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled20 locationsNCT06161974
Recruiting
Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
GliomaAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, Grade IV+5 more
Nuvation Bio Inc.365 enrolled55 locationsNCT05303519
Recruiting
Targeted Pediatric High-Grade Glioma Therapy
Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled20 locationsNCT05843253
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled20 locationsNCT06894979
Recruiting
Early Phase 1
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Phase 2
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
GliomaOligodendrogliomaAstrocytoma+1 more
Stephen Bagley, MD, MSCE55 enrolled1 locationNCT05345002